156 related articles for article (PubMed ID: 38572568)
1. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Munawar U; Theuersbacher J; Steinhardt MJ; Zhou X; Han S; Nerreter S; Vogt C; Kurian S; Keller T; Regensburger AK; Teufel E; Mersi J; Bittrich M; Seifert F; Haider MS; Rasche L; Hillenkamp J; Einsele H; Kampik D; Kortüm KM; Waldschmidt JM
Haematologica; 2024 Apr; ():. PubMed ID: 38572568
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
3. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
4. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
6. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
7. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
8. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
[TBL] [Abstract][Full Text] [Related]
10. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
[TBL] [Abstract][Full Text] [Related]
12. Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
Fazio F; Petrucci MT; Corvatta L; Piciocchi A; Pepa RD; Tacchetti P; Musso M; Zambello R; Belotti A; Bringhen S; Antonioli E; Conticello C; Renzo ND; De Stefano V; Musto P; Gamberi B; Derudas D; Boccadoro M; Offidani M; Morè S
EJHaem; 2024 Jun; 5(3):485-493. PubMed ID: 38895069
[TBL] [Abstract][Full Text] [Related]
13. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma.
Seipel K; Porret N; Wiedemann G; Jeker B; Bacher VU; Pabst T
Curr Issues Mol Biol; 2022 Mar; 44(4):1463-1471. PubMed ID: 35723356
[TBL] [Abstract][Full Text] [Related]
14. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
[TBL] [Abstract][Full Text] [Related]
16. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
Gallin V; Nölle B; Schub N; Roider J
Cornea; 2024 Jun; ():. PubMed ID: 38900711
[TBL] [Abstract][Full Text] [Related]
17. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
18. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Joseph NS; Tai YT; Anderson KC; Lonial S
Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
[TBL] [Abstract][Full Text] [Related]
19. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
Matsumiya W; Karaca I; Ghoraba H; Akhavanrezayat A; Mobasserian A; Hassan M; Regenold J; Yasar C; Liedtke M; Kitazawa K; Nguyen QD
Am J Ophthalmol Case Rep; 2021 Sep; 23():101133. PubMed ID: 34169181
[TBL] [Abstract][Full Text] [Related]
20. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]